Originally Aired: October 28, 2021
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Emerging proteomic technologies have recently matured, and newer techniques now allow larger-scale proteomic characterization. Enhanced aptamer-based assays, one of these more unique technological innovations, have enabled a massively expanded candidate approach that borders on true proteomics in scale; thousands of protein-derived factors can be efficiently assayed simultaneously in a small biologic sample.
In this GEN webinar, our distinguished speaker, Dr. David Lanfear, will explore this new large-scale protein array, SomaScan, using an established heart failure (HF) patient registry to understand how the plasma proteome could meaningfully predict the risk of death or HF worsening and add to best conventional risk stratification, including clinical score and natriuretic peptides. Additionally, Dr. Lanfear will describe how using the circulating proteome to improve risk prediction could add a new tool to help manage patients with HF and contribute to the discovery of novel HF markers and pathways.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.
Produced with support from: